iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale
Insight Molecular Diagnostics Inc IMDX
$3.92
▼ -0.76%
($-0.03)
Open
$3.99
Prev Close
$3.95
Day Range
$3.76 – $4.00
52W Range
$2.42 – $8.51
Market Cap
$128.28M
Beta
1.90
EPS (TTM)
$-1.49
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-12-30 |
| Shares Out. | 32,290,000 |
| Website | imdxinc.com/ ↗ |
| Phone | 19494097600 |
| Employees | 58 |
| Revenue | $239,000 |
| Gross Profit | $157,000 |
| Net Income | -$11.3M |
| Free Cash Flow | -$30.9M |
| Total Assets | $29.4M |
| Total Liabilities | $50.7M |
| Equity | -$21.3M |
About Insight Molecular Diagnostics Inc
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Insight Molecular Diagnostics Inc is a publicly traded company under the ticker symbol IMDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)